KLP Kapitalforvaltning AS Takes Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

KLP Kapitalforvaltning AS purchased a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 24,800 shares of the medical technology company’s stock, valued at approximately $228,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its position in shares of Alphatec by 1.



9% during the third quarter. Charles Schwab Investment Management Inc. now owns 823,222 shares of the medical technology company’s stock worth $4,577,000 after purchasing an additional 15,577 shares in the last quarter.

BNP Paribas Financial Markets increased its position in Alphatec by 73.7% during the third quarter. BNP Paribas Financial Markets now owns 21,603 shares of the medical technology company’s stock worth $120,000 after buying an additional 9,165 shares during the period.

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Alphatec by 28.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,068 shares of the medical technology company’s stock worth $195,000 after buying an additional 7,825 shares during the period.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Alphatec by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 201,672 shares of the medical technology company’s stock valued at $1,121,000 after buying an additional 5,883 shares during the last quarter.

Finally, Centiva Capital LP acquired a new stake in shares of Alphatec in the third quarter valued at approximately $210,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and SellingIn related news, CEO Patrick Miles sold 50,000 shares of Alphatec stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.

00. Following the completion of the transaction, the chief executive officer now directly owns 6,152,544 shares of the company’s stock, valued at approximately $74,015,104.32.

The trade was a 0.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Also, EVP David Sponsel sold 58,283 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.

93. Following the sale, the executive vice president now owns 502,311 shares in the company, valued at approximately $5,379,750.81.

The trade was a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Over the last 90 days, insiders have sold 337,321 shares of company stock valued at $3,828,060. Corporate insiders own 22.80% of the company’s stock.

Alphatec Stock Down 2.2 %ATEC opened at $10.01 on Tuesday.

The business has a 50 day simple moving average of $10.72 and a 200-day simple moving average of $9.20.

Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $14.

54. The stock has a market capitalization of $1.44 billion, a P/E ratio of -7.

82 and a beta of 1.20. The company has a debt-to-equity ratio of 30.

21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC – Get Free Report) last issued its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.

19) by ($0.04). The company had revenue of $176.

79 million for the quarter, compared to analysts’ expectations of $172.74 million. Alphatec had a negative return on equity of 541.

39% and a negative net margin of 31.06%. On average, equities analysts anticipate that Alphatec Holdings, Inc.

will post -1.08 earnings per share for the current fiscal year. Wall Street Analyst Weigh InA number of brokerages have recently commented on ATEC.

HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Barclays lifted their price objective on shares of Alphatec from $20.

00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and set a $16.

00 target price on shares of Alphatec in a research note on Thursday, February 27th. Piper Sandler boosted their price target on Alphatec from $12.00 to $13.

00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Finally, StockNews.com raised Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th.

Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.

67.Read Our Latest Stock Analysis on ATECAbout Alphatec (Free Report)Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers.

The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.Featured StoriesFive stocks we like better than AlphatecRide Out The Recession With These Dividend Kings Options Activity Points to More Volatility for Palantir StockWhat Are Dividend Achievers? An IntroductionNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?Investing in Travel Stocks BenefitsMicroStrategy Sees Insider Buy-Sell Action in Q1Want to see what other hedge funds are holding ATEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alphatec Holdings, Inc.

(NASDAQ:ATEC – Free Report)..